The adaptor molecule MyD88 probably acts as a bridge between the innate and the adaptive immunity, by promoting the activation of antigen presenting cells and consequently priming lymphocytes that exhibit IFN-γ secretion and cytotoxicity profile against tumor cells. This evidence concerns the gene MYD88 and neoplasm.